RxDoctor Payments Data

David Trice, MD

Interventional Cardiology · Fairhope, ALNPI 1508806597

Payments from drug & device makers

$1,316in general payments, 2019–2025

Across 56 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$204
  • Medtronic$203
  • Cardiva Medical, Inc.$145
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$143
  • AstraZeneca$125
  • Johnson & Johnson$82
  • plus $414 from 15 others

What the payments were for

  • Food & beverage$1,316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,316 in reported general payments places this provider in the 10th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$434,686
Medicare patients
1,344
Services billed
3,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban317$339,455
XareltoRivaroxaban118$136,778
Repatha SureclickEvolocumab71$67,567
EntrestoSacubitril/Valsartan64$59,765
MultaqDronedarone Hcl17$24,243
JardianceEmpagliflozin14$12,311
Dofetilide37$9,487
BrilintaTicagrelor11$8,958
Praluent PenAlirocumab13$6,601
Prasugrel Hcl58$6,431
Atorvastatin Calcium459$5,765
Metoprolol Succinate366$4,344
Ranolazine ErRanolazine34$4,283
Nitroglycerin194$3,281
Losartan Potassium248$2,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$339,455317 claims
Johnson & JohnsonXarelto$82$136,778118 claims
NovartisEntresto$35$59,76564 claims
Sanofi-aventis U.S. LLCMultaq$41$24,24317 claims
Boehringer IngelheimJardiance$18$12,31114 claims
AstraZenecaBrilinta$125$8,95811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →